Dr. Gregory's type 1 diabetes research seeks to mechanistically define the deleterious metabolic and cardiovascular effects of iatrogenic hyperinsulinemia caused by peripheral insulin delivery. He is working to translate these findings into therapeutic strategies that will restore an appropriate balance of insulin between the liver and insulin-sensitive peripheral tissues, such as hepatopreferential and oral insulin analogs and intraperitoneal insulin delivery. Ultimately, he aims to quantify the cardiovascular benefits gained when the appropriate insulin balance between hepatic and peripheral tissues is restored. Dr. Gregory's research utilizes the conscious, catheterized canine model to manipulate metabolic and hormonal conditions in vivo. He also conducts cardiometabolic research in humans in the Clinical Research Center at Vanderbilt.


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Response to Comment on Gregory et al. COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective Analysis of the Pandemic's Impact in Type 1 and Type 2 Diabetes. Diabetes Care 2021;44:526-532. Gregory JM, Slaughter JC, Duffus SH, Smith TJ, LeStourgeon LM, Jaser SS, McCoy AB, Luther JM, Giovannetti ER, Boeder S, Pettus JH, Moore DJ (2021) Diabetes Care 44(5): e103-e104
    › Primary publication · 33972321 (PubMed) · PMC8132332 (PubMed Central)
  2. Importance of the route of insulin delivery to its control of glucose metabolism. Edgerton DS, Moore MC, Gregory JM, Kraft G, Cherrington AD (2021) Am J Physiol Endocrinol Metab 320(5): E891-E897
    › Primary publication · 33813879 (PubMed) · PMC8238128 (PubMed Central)
  3. The Dual Burden of Type 1 Diabetes and COVID-19. Gregory JM, Moore DJ (2021) Ann Intern Med 174(5): 703-704
    › Primary publication · 33497267 (PubMed) · PMC8279007 (PubMed Central)
  4. COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective Analysis of the Pandemic's Impact in Type 1 and Type 2 Diabetes. Gregory JM, Slaughter JC, Duffus SH, Smith TJ, LeStourgeon LM, Jaser SS, McCoy AB, Luther JM, Giovannetti ER, Boeder S, Pettus JH, Moore DJ (2021) Diabetes Care 44(2): 526-532
    › Primary publication · 33268335 (PubMed) · PMC7818316 (PubMed Central)
  5. The Peripheral Peril: Injected Insulin Induces Insulin Insensitivity in Type 1 Diabetes. Gregory JM, Cherrington AD, Moore DJ (2020) Diabetes 69(5): 837-847
    › Primary publication · 32312900 (PubMed) · PMC7171956 (PubMed Central)
  6. Roux-en-Y gastric bypass surgery improves hepatic glucose metabolism and reduces plasma kisspeptin levels in morbidly obese patients with type 2 diabetes. Flynn CR, Albaugh VL, Tamboli RA, Gregory JM, Bosompem A, Sidani RM, Winnick JJ (2020) Am J Physiol Gastrointest Liver Physiol 318(2): G370-G374
    › Primary publication · 31709832 (PubMed) · PMC7052573 (PubMed Central)
  7. Increased proportion of time in hybrid closed-loop "Auto Mode" is associated with improved glycaemic control for adolescent and young patients with adult type 1 diabetes using the MiniMed 670G insulin pump. Duffus SH, Ta'ani ZA, Slaughter JC, Niswender KD, Gregory JM (2020) Diabetes Obes Metab 22(4): 688-693
    › Primary publication · 31709736 (PubMed) · PMC7549138 (PubMed Central)
  8. Impact of Acipimox Therapy on Free Fatty Acid Efflux and Endothelial Function in the Metabolic Syndrome: A Randomized Trial. Aday AW, Goldfine AB, Gregory JM, Beckman JA (2019) Obesity (Silver Spring) 27(11): 1812-1819
    › Primary publication · 31571412 (PubMed) · PMC6832806 (PubMed Central)
  9. Aerobic exercise training improves hepatic and muscle insulin sensitivity, but reduces splanchnic glucose uptake in obese humans with type 2 diabetes. Gregory JM, Muldowney JA, Engelhardt BG, Tyree R, Marks-Shulman P, Silver HJ, Donahue EP, Edgerton DS, Winnick JJ (2019) Nutr Diabetes 9(1): 25
    › Primary publication · 31474750 (PubMed) · PMC6717736 (PubMed Central)
  10. Fibrotic Encapsulation Is the Dominant Source of Continuous Glucose Monitor Delays. McClatchey PM, McClain ES, Williams IM, Malabanan CM, James FD, Lord PC, Gregory JM, Cliffel DE, Wasserman DH (2019) Diabetes 68(10): 1892-1901
    › Primary publication · 31399432 (PubMed) · PMC6754243 (PubMed Central)
  11. Peripherally delivered hepatopreferential insulin analog insulin-406 mimics the hypoglycaemia-sparing effect of portal vein human insulin infusion in dogs. Gregory JM, Kraft G, Scott MF, Neal DW, Farmer B, Smith MS, Hastings JR, Madsen P, Kjeldsen TB, Hostrup S, Brand CL, Fledelius C, Nishimura E, Cherrington AD (2019) Diabetes Obes Metab 21(10): 2294-2304
    › Primary publication · 31183936 (PubMed) · PMC8132115 (PubMed Central)
  12. A New Animal Model of Insulin-Glucose Dynamics in the Intraperitoneal Space Enhances Closed-Loop Control Performance. Chakrabarty A, Gregory JM, Moore LM, Williams PE, Farmer B, Cherrington AD, Lord P, Shelton B, Cohen D, Zisser HC, Doyle FJ, Dassau E (2019) J Process Control : 62-73
    › Primary publication · 31178632 (PubMed) · PMC6548466 (PubMed Central)
  13. Iatrogenic Hyperinsulinemia, Not Hyperglycemia, Drives Insulin Resistance in Type 1 Diabetes as Revealed by Comparison With GCK-MODY (MODY2). Gregory JM, Smith TJ, Slaughter JC, Mason HR, Hughey CC, Smith MS, Kandasamy B, Greeley SAW, Philipson LH, Naylor RN, Letourneau LR, Abumrad NN, Cherrington AD, Moore DJ (2019) Diabetes 68(8): 1565-1576
    › Primary publication · 31092478 (PubMed) · PMC6692813 (PubMed Central)
  14. Medical and Psychological Considerations for Carbohydrate-Restricted Diets in Youth With Type 1 Diabetes. Gallagher KAS, DeSalvo D, Gregory J, Hilliard ME (2019) Curr Diab Rep 19(6): 27
    › Primary publication · 31030356 (PubMed)
  15. Enterically delivered insulin tregopil exhibits rapid absorption characteristics and a pharmacodynamic effect similar to human insulin in conscious dogs. Gregory JM, Lautz M, Moore LM, Williams PE, Reddy P, Cherrington AD (2019) Diabetes Obes Metab 21(1): 160-169
    › Primary publication · 30095210 (PubMed) · PMC6281755 (PubMed Central)
  16. Glucose autoregulation is the dominant component of the hormone-independent counterregulatory response to hypoglycemia in the conscious dog. Gregory JM, Rivera N, Kraft G, Winnick JJ, Farmer B, Allen EJ, Donahue EP, Smith MS, Edgerton DS, Williams PE, Cherrington AD (2017) Am J Physiol Endocrinol Metab 313(3): E273-E283
    › Primary publication · 28512154 (PubMed) · PMC5625082 (PubMed Central)
  17. Hepatic glycogen can regulate hypoglycemic counterregulation via a liver-brain axis. Winnick JJ, Kraft G, Gregory JM, Edgerton DS, Williams P, Hajizadeh IA, Kamal MZ, Smith M, Farmer B, Scott M, Neal D, Donahue EP, Allen E, Cherrington AD (2016) J Clin Invest 126(6): 2236-48
    › Primary publication · 27140398 (PubMed) · PMC4887181 (PubMed Central)
  18. Insulin Delivery Into the Peripheral Circulation: A Key Contributor to Hypoglycemia in Type 1 Diabetes. Gregory JM, Kraft G, Scott MF, Neal DW, Farmer B, Smith MS, Hastings JR, Allen EJ, Donahue EP, Rivera N, Winnick JJ, Edgerton DS, Nishimura E, Fledelius C, Brand CL, Cherrington AD (2015) Diabetes 64(10): 3439-51
    › Primary publication · 26085570 (PubMed) · PMC4587648 (PubMed Central)
  19. Type 1 diabetes mellitus. Gregory JM, Moore DJ, Simmons JH (2013) Pediatr Rev 34(5): 203-15
    › Primary publication · 23637249 (PubMed)
  20. Can technological solutions for diabetes replace islet cell function? Gregory JM, Moore DJ (2011) Organogenesis 7(1): 32-41
    › Primary publication · 21289480 (PubMed) · PMC3082032 (PubMed Central)
  21. Mitigating micro-and macro-vascular complications of diabetes beginning in adolescence. Moore DJ, Gregory JM, Kumah-Crystal YA, Simmons JH (2009) Vasc Health Risk Manag : 1015-31
    › Primary publication · 19997571 (PubMed) · PMC2788594 (PubMed Central)